Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Morningstar8d
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
Dupixent was previously granted Orphan Drug ... chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis (PN), chronic spontaneous urticaria (CSU ...
Mena FN26d
Dupixent® (Dupilumab) Sbla Accepted For FDA Priority Review For The Targeted Treatment Of Bullous Pemphigoid (BP)
Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps ...
Yahoo Finance26d
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
Dupixent is now approved in several countries ... moderate-to-severe atopic dermatitis, eosinophilic esophagitis, prurigo nodularis and chronic obstructive pulmonary disease.
Morningstar8d
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Dupixent was previously granted orphan ... chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, and chronic obstructive pulmonary ...